Once‐weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study
Authors' conclusion
These results support the benefits of semaglutide in a real-world setting in adults with T2D in France showing a significant reduction in HbA1c and body weight.
Study context
- Population
- Adults with T2D and ≥1 documented HbA1c value ≤12 weeks before semaglutide initiation, real-world clinical practice in France; 41.6% female, mean age 58.3 years348 completed on treatment
- Participants
- 497 adults
- Outcome
- HbA1c change from baseline to end of study (EOS)
- Follow-up
- ≈30 weeks
Methodological detailsmulticentre, open-label, single-arm, real-world
- Multicentre
- Open-label
- Single-arm
- Real-world
Main finding
As reported in the abstract
HbA1c change from baseline · EOS
Semaglutide
−1.2
mean · 95% CI −1.32–-1.10 · % points
Observational data: associations, not effects.
Secondary outcomes
Body weight (BW) change from baseline · end of study (EOS) (≈30 weeks)
- Mean change in BW
- −4.7 kg (95% CI −5.38; −4.07)
- Effectiveness analysis set
Waist circumference (WC) change from baseline · EOS (≈30 weeks)
- Mean change in WC
- −4.9 cm (95% CI −5.94; −3.88)
- Effectiveness analysis set
Patients achieving HbA1c targets · EOS
- HbA1c <8.0%
- 81.7%
- HbA1c <7.5%
- 67.7%
- HbA1c <7.0%
- 51.6%
- Effectiveness analysis set
Safety
- No new safety concerns were identified
- Full analysis set
Original publication
Once‐weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study. Diabetes Obes Metab. Published 28 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →